NASDAQ:RETA

Delisted

Reta Stock News

Healthcare > Biotechnology

Buy RETA

*Your capital is at risk

$172.36

+0 (+0%)

At Close: Dec 22, 2023

ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - RETA

08:02pm, Tuesday, 24'th Nov 2020

New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between

Rosen, Global Investor Counsel, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - RETA

02:30pm, Saturday, 21'st Nov 2020

New York, New York--(Newsfile Corp. - November 21, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

03:46pm, Wednesday, 18'th Nov 2020

Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reata Pharmac

ROSEN, LEADING TRIAL ATTORNEYS, Reminds Reata Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - RETA

03:33pm, Wednesday, 18'th Nov 2020

NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 a

ROSEN, A LEADING LAW FIRM, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action - RETA

04:04pm, Friday, 13'th Nov 2020

New York, New York--(Newsfile Corp. - November 13, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) betwe

DEADLINE FOR RETA INVESTORS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Reata Pharmaceuticals Inc.

03:17pm, Wednesday, 11'th Nov 2020

New York, New York--(Newsfile Corp. - November 11, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class a

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q3 2020 Results - Earnings Call Transcript

02:17pm, Monday, 09'th Nov 2020

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q3 2020 Results - Earnings Call Transcript

Were Hedge Funds Wrong About Reata Pharmaceuticals, Inc. (RETA)?

11:20am, Monday, 09'th Nov 2020

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in ( Recession is Imminent: We Need A Travel Ban NOW

DEADLINE FOR RETA INVESTORS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Reata Pharmaceuticals Inc.

09:09am, Monday, 09'th Nov 2020

New York, New York--(Newsfile Corp. - November 9, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class ac

Recap: Reata Pharmaceuticals Q3 Earnings

07:27am, Monday, 09'th Nov 2020

Shares of Reata Pharmaceuticals (NASDAQ:RETA) rose 17.5% in pre-market trading after the company reported Q3 results.

Reata Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results and Provides an Update on Business Operations and Clinical Development Programs

06:45am, Monday, 09'th Nov 2020

REPORTED POSITIVE YEAR 2 DATA FROM THE PIVOTAL CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH CHRONIC KIDNEY DISEASE CAUSED BY ALPORT SYNDROME

DEADLINE FOR RETA INVESTORS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Reata Pharmaceuticals Inc.

06:42pm, Friday, 06'th Nov 2020

New York, New York--(Newsfile Corp. - November 6, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class ac

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm - RETA

06:30pm, Wednesday, 04'th Nov 2020

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 an

RETA LOSS ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Reata Pharmaceuticals Inc.

06:19pm, Wednesday, 04'th Nov 2020

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the lead plaintiff deadline in a securities class action that has been

Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020

05:30pm, Monday, 02'nd Nov 2020

PLANO, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced th

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by